Impact of Direct-acting Antivirals for Hepatitis C Virus Therapy on Tacrolimus Dosing in Liver Transplant Recipients

Overview

Journal Transpl Infect Dis

Specialties General Surgery
Infectious Diseases

Date 2019 Mar 19

PMID 30884055

Citations 4

Authors

Alexandra L Bixby

Linda Fitzgerald

Rachael Leek

Jessica Mellinger

Pratima Sharma

Sarah Tischer

Affiliations

Soon will be listed here.

Abstract

Introduction: Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) management post-liver transplant. As HCV clears during DAA treatment, hepatic metabolism improves, resulting in decreased tacrolimus concentrations that may require dose adjustment. The purpose of this study was to determine appropriate management of immunosuppression in liver transplant recipients during and following treatment of HCV.

Methods: This study was a single-center retrospective analysis of 71 liver transplant recipients who were treated for HCV with DAAs. The primary outcome was change in dose-normalized tacrolimus concentrations from the start of DAA treatment to 12 weeks following therapy.

Results: The mean change in log-transformed dose-normalized tacrolimus concentrations was a reduction of 0.43 ng/mL/mg (95% CI; 0.26-0.60, P < 0.0001). The greatest decrease occurred in the first 4 weeks of treatment, after which levels stabilized. The overall mean tacrolimus concentration was 4.8 ng/mL (±2.5). Two patients (3%) developed acute cellular rejection and two patients (3%) had graft loss and died.

Conclusion: From the start of treatment to 12 weeks post-DAA therapy, liver transplant recipients experienced a significant decrease in dose-normalized tacrolimus concentrations. In conclusion, close monitoring of tacrolimus concentrations is warranted during and following treatment with DAAs, as dose increases may be indicated in order to maintain therapeutic concentrations to prevent graft rejection.

Citing Articles

Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil.

Pacheco L, Ventura P, Kist R, Garcia V, Meinerz G, Tovo C Rev Inst Med Trop Sao Paulo. 2023; 65:e59.

PMID: 38055377 PMC: 10703500. DOI: 10.1590/S1678-9946202365059.

Immunosuppression Monitoring-What Clinician Needs to Know?.

Wadhawan M, Gupta C J Clin Exp Hepatol. 2023; 13(4):691-697.

PMID: 37440936 PMC: 10333948. DOI: 10.1016/j.jceh.2023.01.003.

Breakthroughs and challenges in the management of pediatric viral hepatitis.

Nicastro E, Norsa L, Di Giorgio A, Indolfi G, DAntiga L World J Gastroenterol. 2021; 27(20):2474-2494.

PMID: 34092970 PMC: 8160618. DOI: 10.3748/wjg.v27.i20.2474.

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.

Zhang J, Sun W, Lin J, Tian Y, Ma L, Zhang L BMC Infect Dis. 2019; 19(1):645.

PMID: 31324230 PMC: 6642594. DOI: 10.1186/s12879-019-4217-7.

References

Latorre A, Morales E, Gonzalez E, Herrero J, Ortiz M, Sierra P . Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. Transplant Proc. 2002; 34(1):63-4. DOI: 10.1016/s0041-1345(01)02678-1. View

Nair S, Satapathy S, Gonzalez H . Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant. Exp Clin Transplant. 2016; 15(3):314-319. DOI: 10.6002/ect.2015.0289. View

Frye R, Zgheib N, Matzke G, Chaves-Gnecco D, Rabinovitz M, Shaikh O . Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther. 2006; 80(3):235-45. DOI: 10.1016/j.clpt.2006.05.006. View

Mutimer D . Pre- and Post-Transplant Treatment of Viral Hepatitis C. Dig Dis. 2017; 35(4):347-350. DOI: 10.1159/000456586. View

Martin P, DiMartini A, Feng S, Brown Jr R, Fallon M . Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014; 59(3):1144-65. DOI: 10.1002/hep.26972. View

Walter T, Dumortier J, Guillaud O, Hervieu V, PALIARD P, Scoazec J . Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant. 2007; 7(1):177-84. DOI: 10.1111/j.1600-6143.2006.01590.x. View

Thervet E, Anglicheau D, King B, Schlageter M, Cassinat B, Beaune P . Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003; 76(8):1233-5. DOI: 10.1097/01.TP.0000090753.99170.89. View

Sharma P, Hosmer A, Appelman H, McKenna B, Jafri M, Sullivan P . Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatol Int. 2015; 7(4):990-9. PMC: 4371864. DOI: 10.1007/s12072-013-9436-1. View

Levitsky J, Fiel M, Norvell J, Wang E, Watt K, Curry M . Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012; 142(5):1132-1139.e1. DOI: 10.1053/j.gastro.2012.01.030. View

10.

Nookala A, Crismale J, Schiano T, Te H, Ahn J, Robertazzi S . Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients. Clin Transplant. 2018; 32(3):e13198. DOI: 10.1111/ctr.13198. View

11.

Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M . CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics. 2004; 14(7):471-8. DOI: 10.1097/01.fpc.0000114747.08559.49. View

12.

Mansour M, Hill L, Kerr J . Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation. Transpl Infect Dis. 2018; 20(6):e12972. DOI: 10.1111/tid.12972. View

13.

Smolders E, Pape S, de Kanter C, van den Berg A, Drenth J, Burger D . Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?. Int J Antimicrob Agents. 2017; 49(3):379-382. DOI: 10.1016/j.ijantimicag.2016.12.004. View

14.

Chan C, Schiano T, Agudelo E, Haydek J, Hoteit M, Laurito M . Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. Am J Transplant. 2018; 18(10):2506-2512. DOI: 10.1111/ajt.15053. View

15.

Poordad F, Schiff E, Vierling J, Landis C, Fontana R, Yang R . Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5):1493-505. PMC: 5069651. DOI: 10.1002/hep.28446. View

16.

Morcos P, Moreira S, Brennan B, Blotner S, Shulman N, Smith P . Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol. 2013; 69(10):1777-84. DOI: 10.1007/s00228-013-1525-5. View

17.

Kugelmas M, Osgood M, Trotter J, Bak T, Wachs M, Forman L . Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003; 9(11):1159-65. DOI: 10.1053/jlts.2003.50233. View

18.

Saab S, Rheem J, Jimenez M, Bau S, Choi G, Durazo F . Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl Hepatol. 2016; 4(1):32-8. PMC: 4807141. DOI: 10.14218/JCTH.2016.00001. View

19.

Ueda Y, Ikegami T, Akamatsu N, Soyama A, Shinoda M, Goto R . Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017; 52(8):986-991. DOI: 10.1007/s00535-017-1310-9. View

20.

Vanhove T, Bouwsma H, Hilbrands L, Swen J, Spriet I, Annaert P . Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. Am J Transplant. 2017; 17(9):2372-2380. DOI: 10.1111/ajt.14232. View